| 臺大學術典藏 |
2022-01-24T09:30:58Z |
Serum hepatitis B core-related antigen level stratifies risk of disease progression in chronic hepatitis B patients with intermediate viral load
|
Tseng T.-C.; CHUN-JEN LIU; Yang W.-T.; Hsu C.-Y.; Hong C.-M.; Su T.-H.; Tsai C.-H.; Chen C.-L.; Yang H.-C.; Liu C.-H.; Chen H.-H.; Chen P.-J.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:30:56Z |
Combined viral quasispecies diversity and hepatitis B core-related antigen predict off-nucleos(t)ide analog durability in HBeAg-negative patients
|
Cheng H.-R.; Yang H.-C.; Lin S.-R.; Yang T.-Y.; Lin Y.-Y.; Su T.-H.; Tseng T.-C.; CHUN-JEN LIU; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:30:56Z |
Whole genome deep sequencing analysis of viral quasispecies diversity and evolution in HBeAg seroconverters
|
Lin S.-R.; Yang T.-Y.; Peng C.-Y.; Lin Y.-Y.; Dai C.-Y.; Wang H.-Y.; Su T.-H.; Tseng T.-C.; Liu I.-J.; Cheng H.-R.; Shen Y.-C.; Wu F.-Y.; CHUN-JEN LIU; Chen D.-S.; Chen P.-J.; Yang H.-C.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:30:56Z |
Evolution of estimated glomerular filtration rate in human immunodeficiency virus and hepatitis C virus-coinfected patients receiving sofosbuvir-based direct-acting antivirals and antiretroviral therapy
|
Liu C.-H.; Sun H.-Y.; Hsieh S.-M.; Liu W.-C.; Sheng W.-H.; CHUN-JEN LIU; Su T.-H.; Tseng T.-C.; Chen P.-J.; Hung C.-C.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:30:52Z |
Correction to: Combined viral quasispecies diversity and hepatitis B core-related antigen predict off-nucleos(t)ide analog durability in HBeAg-negative patients (Hepatology International, (2021), 15, 3, (582-592), 10.1007/s12072-021-10186-7)
|
Cheng H.-R.; Yang H.-C.; Lin S.-R.; Yang T.-Y.; Lin Y.-Y.; Su T.-H.; Tseng T.-C.; CHUN-JEN LIU; Kao J.-H. |
| 臺大學術典藏 |
2022-01-13T08:46:00Z |
High serum lipopolysaccharide-binding protein level in chronic hepatitis C viral infection is reduced by anti-viral treatments
|
Nien H.-C.; Hsu S.-J.; Su T.-H.; PO-JEN YANG; Sheu J.-C.; Wang J.-T.; Chow L.-P.; Chen C.-L.; Kao J.-H.; Yang W.-S. |
| 臺大學術典藏 |
2022-01-07T06:05:52Z |
Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: A randomised trial
|
Liu C.-H.; Liu C.-J.; Huang C.-F.; Lin J.-W.; Dai C.-Y.; Liang C.-C.; Huang J.-F.; Hung P.-H.; Tsai H.-B.; Tsai M.-K.; CHIH-YUAN LEE; Chen S.-I.; Yang S.-S.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; Yu M.-L.; Kao J.-H. |
| 國立成功大學 |
2022 |
Serum cytokine/chemokine profiles predict hepatitis B reactivation in HBV/HCV co-infected subjects receiving direct-acting antiviral agents
|
Huang, S.-C.;Cheng, P.-N.;Liu, C.-H.;Yang, H.-C.;Su, T.-H.;Tseng, Tseng T.-C.;Chen, P.-J.;Kao, J.-H.;Liu, C.-J. |
| 臺大學術典藏 |
2021-12-01T02:29:06Z |
Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan
|
Liu C.-H.; Liu C.-J.; CHIEN-CHING HUNG; Hsieh S.-M.; Su T.-H.; Sun H.-Y.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-10-27T03:22:18Z |
Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era
|
Cheng C.-L.; Huang S.-C.; Chen J.-H.; Wei C.-H.; Fang W.-Q.; Su T.-H.; CHANG-TSU YUAN; Liu J.-H.; Chuang M.-K.; Tien H.-F. |
| 臺大學術典藏 |
2021-09-27T05:32:39Z |
Evolution of estimated glomerular filtration rate in human immunodeficiency virus and hepatitis C virus-coinfected patients receiving sofosbuvir-based direct-acting antivirals and antiretroviral therapy
|
Liu C.-H.; Sun H.-Y.; Hsieh S.-M.; Liu W.-C.; WANG-HUEI SHENG; Liu C.-J.; Su T.-H.; Tseng T.-C.; Chen P.-J.; Hung C.-C.; Kao J.-H. |
| 臺大學術典藏 |
2021-09-04T06:12:40Z |
APRI-M6 for predicting long-term outcome of chronic hepatitis C patients after interferon-based therapy: More questions than answers [5]
|
Su T.-H.; JIA-HORNG KAO; Chen D.-S. |
| 臺大學術典藏 |
2021-09-04T06:12:33Z |
Acute fatty liver of pregnancy with concurrent acute hepatitis B virus infection
|
Su T.-H.; Liu C.-J.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:12:18Z |
Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B
|
Su T.-H.; Hsu C.-S.; Chen C.-L.; Liu C.-H.; Huang Y.-W.; Tseng T.-C.; Liu C.-J.; Chen P.-J.; Lai M.-Y.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:12:14Z |
HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses
|
Yu M.-L.; Lee C.-M.; Chuang W.-L.; Lu S.-N.; Dai C.-Y.; Huang J.-F.; Lin Z.-Y.; Hu T.-I.; Chen C.-H.; Hung C.-.; Wang J.-H.; Chen C.-L.; JIA-HORNG KAO; Lai M.-Y.; Liu C.-H.; Su T.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; Chen P.-J.; Liu C.-J.; Chen D.-S. |
| 臺大學術典藏 |
2021-09-04T06:12:09Z |
The clinical significance of occult hepatitis B transfusion in Taiwan - a look-back study
|
Su T.-H.; Chen P.-J.; Chen T.-C.; Cheng H.-R.; Li L.; Lin K.-S.; JIA-HORNG KAO; Chen D.-S.; Liu C.-J. |
| 臺大學術典藏 |
2021-09-04T06:12:03Z |
High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load
|
Tseng T.-C.; Liu C.-J.; Yang H.-C.; Su T.-H.; Wang C.-C.; Chen C.-L.; Kuo S.F.-T.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:12:02Z |
Serum hepatitis B virus-DNA levels correlate with long-term adverse outcomes in spontaneous hepatitis B e antigen seroconverters
|
Tseng T.-C.; Liu C.-J.; Chen C.-L.; Wang C.-C.; Su T.-H.; Kuo S.F.-T.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:12:01Z |
Host genetic variants and hepatitis b virologic features in HBeAg-negative hepatitis B carriers with long-term biochemical remission
|
Lin C.-L.; Tseng T.-C.; Su T.-H.; Liu C.-J.; Chen P.-J.; Lai M.-Y.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:12:00Z |
Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy
|
Liu C.-H.; Liang C.-C.; Liu C.-J.; Tseng T.-C.; Lin C.-L.; Yang S.-S.; Su T.-H.; Hsu S.-J.; Lin J.-W.; Chen J.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:12:00Z |
Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load
|
Tseng T.-C.; Liu C.-J.; Yang H.-C.; Su T.-H.; Wang C.-C.; Chen C.-L.; Fang-Tzu Kuo S.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:12:00Z |
Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin
|
Liu C.-H.; Liang C.-C.; Liu C.-J.; Tseng T.-C.; Lin C.-L.; Yang S.-S.; Su T.-H.; Lin J.-W.; Chen J.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:55Z |
Young chronic hepatitis b patients with nucleos(t)ide analogue-induced hepatitis b e antigen seroconversion have a higher risk of HBV reactivation
|
Tseng T.-C.; Liu C.-J.; Su T.-H.; Yang H.-C.; Wang C.-C.; Chen C.-L.; Kuo S.F.-T.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:54Z |
Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir
|
Wang C.-C.; Tseng K.-C.; Peng C.-Y.; Hsieh T.-Y.; Lin C.-L.; Su T.-H.; Tseng T.-C.; Hsu C.-S.; Lin H.H.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:52Z |
Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion
|
Yang H.-C.; Chen C.-L.; Shen Y.-C.; Peng C.-Y.; Liu C.-J.; Tseng T.-C.; Su T.-H.; Chuang W.-L.; Yu M.-L.; Dai C.-Y.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
